Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy

Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy

Abstract Background Melanoma patients frequently develop brain metastases. The most widely used score to predict survival is the molGPA based on a mixed treatment of stereotactic radiotherapy (SRT) and whole brain radiotherapy (WBRT). In addition, systemic therapy was not considered. We therefore ai...

Full description

Bibliographic Details
Main Authors: Jana Schaule, Stephanie G. C. Kroeze, Oliver Blanck, Susanne Stera, Klaus H. Kahl, Falk Roeder, Stephanie E. Combs, David Kaul, An Claes, Markus M. Schymalla, Sonja Adebahr, Franziska Eckert, Fabian Lohaus, Nasrin Abbasi-Senger, Guido Henke, Marcella Szuecs, Michael Geier, Nora Sundahl, Daniel Buergy, Reinhard Dummer, Matthias Guckenberger
Format: Article
Language:English
Published: BMC 2020-06-01
Series:Radiation Oncology
Subjects:
molGPA
Melanoma
Stereotactic
Brain metastases
Immunotherapy
Targeted therapy
Online Access:http://link.springer.com/article/10.1186/s13014-020-01558-8

Internet

http://link.springer.com/article/10.1186/s13014-020-01558-8

Similar Items